The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future

Stefano Ferrari, Emanuela Palmerini, Eric L. Staals, Mario Mercuri, Bertoni Franco, Piero Picci, Gaetano Bacci

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The Bone Tumor Center of the "Istituto Ortopedico Rizzoli" was established in 1955 with the aim of studying and treating the musculoskeletal tumors. Between 1959 and 2006, 1245 patients with high grade nonmetastatic osteosarcoma of the extremity were treated at our Institute. Most of them were enrolled in study protocols. In the "prechemotherapy era", the cure rate was 11%, with an amputation rate of 90%. Our first experience with adjuvant chemotherapy was in 1972. A total of 223 patients received adjuvant chemotherapy, with a disease-free survival (DFS) ranging from 45% to 53%, according to the chemotherapy protocol used. With the introduction of neoadjuvant chemotherapy, the resection rate increased and reached 94%, when high dose fosfamide was added to standard doses of methotrexate, cisplatin, and adriamycin. In the last few years, the results of treatment of nonmetastatic osteosarcoma of the extremity have reached a plateau (64% five-year DFS), and strategies of dose intensification are not able to improve the prognosis. Not only new active drugs, but also different approaches to the disease, are needed. In this regard, we are now investigating tumor microenvironment-targeted agents and chemotherapy protocols based on prospective biological stratification of patients. Collaborative projects with international groups and institutions are crucial for this rare disease.

Original languageEnglish
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages275-287
Number of pages13
Volume152
ISBN (Print)9781441902832
DOIs
Publication statusPublished - 2010

Publication series

NameCancer Treatment and Research
Volume152
ISSN (Print)09273042

Fingerprint

Osteosarcoma
Extremities
Adjuvant Chemotherapy
Drug Therapy
Disease-Free Survival
Tumor Microenvironment
Rare Diseases
Amputation
Methotrexate
Doxorubicin
Cisplatin
Neoplasms
Therapeutics
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Ferrari, S., Palmerini, E., Staals, E. L., Mercuri, M., Franco, B., Picci, P., & Bacci, G. (2010). The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future. In Cancer Treatment and Research (Vol. 152, pp. 275-287). (Cancer Treatment and Research; Vol. 152). Kluwer Academic Publishers. https://doi.org/10.1007/978-1-4419-0284-9_14

The treatment of nonmetastatic high grade osteosarcoma of the extremity : Review of the Italian Rizzoli experience. Impact on the future. / Ferrari, Stefano; Palmerini, Emanuela; Staals, Eric L.; Mercuri, Mario; Franco, Bertoni; Picci, Piero; Bacci, Gaetano.

Cancer Treatment and Research. Vol. 152 Kluwer Academic Publishers, 2010. p. 275-287 (Cancer Treatment and Research; Vol. 152).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ferrari, S, Palmerini, E, Staals, EL, Mercuri, M, Franco, B, Picci, P & Bacci, G 2010, The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future. in Cancer Treatment and Research. vol. 152, Cancer Treatment and Research, vol. 152, Kluwer Academic Publishers, pp. 275-287. https://doi.org/10.1007/978-1-4419-0284-9_14
Ferrari S, Palmerini E, Staals EL, Mercuri M, Franco B, Picci P et al. The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future. In Cancer Treatment and Research. Vol. 152. Kluwer Academic Publishers. 2010. p. 275-287. (Cancer Treatment and Research). https://doi.org/10.1007/978-1-4419-0284-9_14
Ferrari, Stefano ; Palmerini, Emanuela ; Staals, Eric L. ; Mercuri, Mario ; Franco, Bertoni ; Picci, Piero ; Bacci, Gaetano. / The treatment of nonmetastatic high grade osteosarcoma of the extremity : Review of the Italian Rizzoli experience. Impact on the future. Cancer Treatment and Research. Vol. 152 Kluwer Academic Publishers, 2010. pp. 275-287 (Cancer Treatment and Research).
@inproceedings{dfea7af15aa84ca79cd1d470c20e488c,
title = "The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future",
abstract = "The Bone Tumor Center of the {"}Istituto Ortopedico Rizzoli{"} was established in 1955 with the aim of studying and treating the musculoskeletal tumors. Between 1959 and 2006, 1245 patients with high grade nonmetastatic osteosarcoma of the extremity were treated at our Institute. Most of them were enrolled in study protocols. In the {"}prechemotherapy era{"}, the cure rate was 11{\%}, with an amputation rate of 90{\%}. Our first experience with adjuvant chemotherapy was in 1972. A total of 223 patients received adjuvant chemotherapy, with a disease-free survival (DFS) ranging from 45{\%} to 53{\%}, according to the chemotherapy protocol used. With the introduction of neoadjuvant chemotherapy, the resection rate increased and reached 94{\%}, when high dose fosfamide was added to standard doses of methotrexate, cisplatin, and adriamycin. In the last few years, the results of treatment of nonmetastatic osteosarcoma of the extremity have reached a plateau (64{\%} five-year DFS), and strategies of dose intensification are not able to improve the prognosis. Not only new active drugs, but also different approaches to the disease, are needed. In this regard, we are now investigating tumor microenvironment-targeted agents and chemotherapy protocols based on prospective biological stratification of patients. Collaborative projects with international groups and institutions are crucial for this rare disease.",
author = "Stefano Ferrari and Emanuela Palmerini and Staals, {Eric L.} and Mario Mercuri and Bertoni Franco and Piero Picci and Gaetano Bacci",
year = "2010",
doi = "10.1007/978-1-4419-0284-9_14",
language = "English",
isbn = "9781441902832",
volume = "152",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "275--287",
booktitle = "Cancer Treatment and Research",

}

TY - GEN

T1 - The treatment of nonmetastatic high grade osteosarcoma of the extremity

T2 - Review of the Italian Rizzoli experience. Impact on the future

AU - Ferrari, Stefano

AU - Palmerini, Emanuela

AU - Staals, Eric L.

AU - Mercuri, Mario

AU - Franco, Bertoni

AU - Picci, Piero

AU - Bacci, Gaetano

PY - 2010

Y1 - 2010

N2 - The Bone Tumor Center of the "Istituto Ortopedico Rizzoli" was established in 1955 with the aim of studying and treating the musculoskeletal tumors. Between 1959 and 2006, 1245 patients with high grade nonmetastatic osteosarcoma of the extremity were treated at our Institute. Most of them were enrolled in study protocols. In the "prechemotherapy era", the cure rate was 11%, with an amputation rate of 90%. Our first experience with adjuvant chemotherapy was in 1972. A total of 223 patients received adjuvant chemotherapy, with a disease-free survival (DFS) ranging from 45% to 53%, according to the chemotherapy protocol used. With the introduction of neoadjuvant chemotherapy, the resection rate increased and reached 94%, when high dose fosfamide was added to standard doses of methotrexate, cisplatin, and adriamycin. In the last few years, the results of treatment of nonmetastatic osteosarcoma of the extremity have reached a plateau (64% five-year DFS), and strategies of dose intensification are not able to improve the prognosis. Not only new active drugs, but also different approaches to the disease, are needed. In this regard, we are now investigating tumor microenvironment-targeted agents and chemotherapy protocols based on prospective biological stratification of patients. Collaborative projects with international groups and institutions are crucial for this rare disease.

AB - The Bone Tumor Center of the "Istituto Ortopedico Rizzoli" was established in 1955 with the aim of studying and treating the musculoskeletal tumors. Between 1959 and 2006, 1245 patients with high grade nonmetastatic osteosarcoma of the extremity were treated at our Institute. Most of them were enrolled in study protocols. In the "prechemotherapy era", the cure rate was 11%, with an amputation rate of 90%. Our first experience with adjuvant chemotherapy was in 1972. A total of 223 patients received adjuvant chemotherapy, with a disease-free survival (DFS) ranging from 45% to 53%, according to the chemotherapy protocol used. With the introduction of neoadjuvant chemotherapy, the resection rate increased and reached 94%, when high dose fosfamide was added to standard doses of methotrexate, cisplatin, and adriamycin. In the last few years, the results of treatment of nonmetastatic osteosarcoma of the extremity have reached a plateau (64% five-year DFS), and strategies of dose intensification are not able to improve the prognosis. Not only new active drugs, but also different approaches to the disease, are needed. In this regard, we are now investigating tumor microenvironment-targeted agents and chemotherapy protocols based on prospective biological stratification of patients. Collaborative projects with international groups and institutions are crucial for this rare disease.

UR - http://www.scopus.com/inward/record.url?scp=77953666756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953666756&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0284-9_14

DO - 10.1007/978-1-4419-0284-9_14

M3 - Conference contribution

C2 - 20213396

AN - SCOPUS:77953666756

SN - 9781441902832

VL - 152

T3 - Cancer Treatment and Research

SP - 275

EP - 287

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -